Navigation Links
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
Date:1/7/2009

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which prevents the entry of HIV into target cells and significantly raises the potential genetic barrier to resistance with IQP-0410 therapy. Preclinical pharmacokinetic and toxicology studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against multi-drug resistant virus strains obtained from patients failing long courses of therapy with currently approved RT and protease inhibitors. The compound is well suited for use as a component of primary HAART regimens as well as a salvage therapy option. Preclinical studies have also demonstrated the ability of the compound to be used in combination with all other approved HIV drugs.

"The submission of this IND represents a critical milestone in the therapeutic development of the pyrimidinedione class of molecules as potential new HIV drugs and an important success in the strategic drug development initiatives between ImQuest and Samjin Pharmaceutical Co. Ltd of Seoul, KOREA," said Dr. Robert W. Buckheit, Jr., Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "We believe that IQP-0410 will be a new and novel addition to the armamentarium of HIV drugs available and provide HIV-infected individuals with a safe and effective alter
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
4. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
7. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... U.S. Food and Drug Administration approved a new type 2 ... class of once-a-week injectable drugs that help manage blood sugar ... is a new treatment option, which can be used alone ... levels in the overall management of type 2 diabetes," Dr. ... Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... published today in the online journal PLoS Outbreaks ... West Africa by the end of the month if ... State University and Harvard University researchers also discovered through ... significantly increased in August in Liberia and Guinea, around ... place, indicating that the mass quarantine efforts may have ...
(Date:9/19/2014)... September 19, 2014 Famous Vancouver company, ... that it has now become a one-stop-solution for heating, ... businesses in Vancouver. The company has achieved this status ... to its customers. While there are many companies that ... have a single vendor who can offer all of ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2
... to try it than highest scorers, study found , ... young males has been linked to a much higher ... their most intelligent counterparts, researchers say. , The analysis, ... doesn,t prove that low intelligence causes suicide. Instead, it ...
... Researchers at Mount Sinai School of Medicine have developed ... in reversing advanced heart failure. SERCA2a (produced as MYDICAR) ... an enzyme that enables the failing heart to pump ... through a routine minimally invasive cardiac catheterization was safe ...
... Geneva 3 June 2010. Following a workshop hosted by ... and physicists today published a strategy for harnessing physics ... long history of application in medicine. Today,s news recognises ... collaboration. The workshop, which was the first of ...
... , ... round of 30 Days of Intentions to mark the mid-point of 2010. , ... Los Angeles, CA (PRWEB) June 3, 2010 -- This ... 2010. The 30 Days of Intentions is a challenge to the internet community to commit to ...
... Theurer Cancer Center at Hackensack University Medical Center announced ... abstracts on treatment and diagnostic progress in many different ... Society of Clinical Oncology (ASCO) in Chicago, IL from ... Cancer Center, we,re dedicated to providing extraordinary cancer care ...
... ... supplements, drugs, and medical conditions that can affect the color and odor of urine. , ... Boston, MA (Vocus) June 4, 2010 -- If ... beets turns urine pink or red—which can be alarming because it looks like blood in the ...
Cached Medicine News:Health News:Low IQ Among Males Raises Suicide Risk 2Health News:New gene therapy proves effective in treating severe heart failure 2Health News:Physicists and medics set out strategy on physics for health 2Health News:Intent.com Launches 30 Days of Intentions and Announces Winners of 2010 Intent Web Awards 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Color, Odor Changes in Urine Usually -- But Not Always -- Harmless, Reports Harvard Women's Health Watch 2
Inquire...
... are accurate to 1 mm. In vivo results ... patients encapsulation scar tissue. Encapsulation scar tissue can ... therefore actual projection may vary from patient to ... surgeon with a scalpel or surgical scissors. All ...
... IQmarkTM Diagnostic Workstation Software offers a ... that digitally stores many different diagnostic ... Microsofts open-architecture products in mind, our ... integration (using ActiveX controls), networking, central ...
... engineered to set a new standard for ... enter the patient demographics, select auto report ... based system uses the latest in software ... of the IQmark Holter algorithm. Simple, intuitive ...
Medicine Products: